Q1 Earnings Forecast for Soligenix Issued By Zacks Small Cap

Soligenix, Inc. (NASDAQ:SNGX) – Stock analysts at Zacks Small Cap issued their Q1 2025 earnings estimates for shares of Soligenix in a research report issued to clients and investors on Wednesday, March 26th. Zacks Small Cap analyst D. Bautz forecasts that the biopharmaceutical company will earn ($0.67) per share for the quarter. The consensus estimate for Soligenix’s current full-year earnings is ($4.65) per share. Zacks Small Cap also issued estimates for Soligenix’s Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.79) EPS and FY2027 earnings at ($1.75) EPS.

Soligenix (NASDAQ:SNGX) last posted its quarterly earnings results on Friday, March 21st. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.19). Soligenix had a negative net margin of 1,473.38% and a negative return on equity of 223.29%. The company had revenue of $0.20 million during the quarter, compared to analysts’ expectations of $0.20 million. During the same quarter last year, the company earned ($12.66) earnings per share.

Soligenix Stock Performance

NASDAQ SNGX opened at $2.27 on Thursday. The stock’s fifty day moving average is $2.35 and its two-hundred day moving average is $3.08. The firm has a market capitalization of $5.70 million, a P/E ratio of -0.30 and a beta of 2.03. Soligenix has a fifty-two week low of $1.83 and a fifty-two week high of $14.92.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Soligenix stock. Geode Capital Management LLC raised its position in Soligenix, Inc. (NASDAQ:SNGX) by 42.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 26,094 shares of the biopharmaceutical company’s stock after purchasing an additional 7,729 shares during the quarter. Geode Capital Management LLC owned about 1.04% of Soligenix worth $71,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 3.60% of the company’s stock.

About Soligenix

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.